Larimar Therapeutics Inc (LRMR) Stock Price, Quote & News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 844-511-9056

Website: larimartx.com

Address:

Three Bala Plaza East, Suite 506, Bala Cynwyd, United States

Buss Jul. 13 at 7:37 PM

$LRMR Hourly time frame further detailing Friday's consolidating inside day of Thursday's trading action, as well as the ascending wedge that could lead to further breakout potentiating short covering activity. Bulls clearly meeting Ichimoku criterion for maintaining bullish control, therefore the overarching question is can upside momentum be further established based up this TA alone, or is bullish momentum primed for a near-term setback at this 3.50 level?

0 · Reply

Buss Jul. 13 at 7:28 PM

$LRMR Massive build-up of the potential of reduced overhead supply @ the 3 1/2 level, thereby embodying the potential for an upside breakout that has been developing since mid-May. LRMR nicely consolidating the bull flag breakout of early July, however this forthcoming week will be critical to advance this breakout and NOT otherwise breakdown. MACD has PLENTY of room to run, so perhaps this week will be THE week for the LRMR long faithful contingent. Enjoy your Sunday all. Be Blessed! :)

0 · Reply

Biobullshitsniffer Jul. 12 at 3:41 PM

$LRMR Huge options calls expiring in November.

0 · Reply

Buss Jul. 10 at 10:42 PM

$LRMR The short's nightmare...the dreaded double-bottom "W" that slowly but surely grinds higher. Today's volume was basically average as it has been over the course of the last 2 weeks, with the expected selling/distribution @ the 3 1/2 level being observed, although this overhead supply is being taken up quite nicely without any significant pull back. Once she clears the 3 1/2 level on a closing basis, could quickly see that 200 day MA that looms directly overhead @ the $4 level.

0 · Reply

Primitivetablemaker Jul. 9 at 2:14 PM

$SYTA $LRMR $RNAZ

0 · Reply

Buss Jul. 9 at 1:01 AM

$LRMR "The Heat Is On" :) https://www.youtube.com/watch?v=uZD8HKVKneI&list=RDuZD8HKVKneI&start_radio=1

0 · Reply

Buss Jul. 9 at 1:00 AM

$LRMR Should clear all sell stops @ 3 1/2 tomorrow that are presently trying to prevent further upside advance which we witnessed each time 3.49 was probed during today's session. Once this occurs and is cleared on a volume surge, shorts will be compelled to cover and with any real volume Glen Frey's favorite adaptation "The 'Squeeze' Is On" will be heard in chat rooms and on message boards all o'er the land as his surname becomes LRMR's favorite dish...i.e., "deep-FREY-ED".

0 · Reply

Musket1776 Jul. 8 at 5:46 PM

$LRMR My wife died from Friedreicks Ataxia in 2022 so I have a high interest in this drugs development addressing the condition. But ironically I owned shares in Zafgen in 2015 that was working on an obesity drug (it had two fatalities in third trials and the fda shut it down permanently.) But Zafgen merged with another company forming lrmr so here I am back in a company that was actually my biggest loss ever in trading (lost 15k in a day when the death was announced and the stock crashed, taught me a valuable lesson to use stop loss!)

1 · Reply

Dani_G_German Jul. 8 at 2:32 PM

$LRMR

0 · Reply

G101SPM Jul. 8 at 11:08 AM

$LRMR $3.25 bid. DAC (8) $3.44. EXIT $11.00 (long term). BRIEF: Today announced the publication of two peer-reviewed articles highlighting nonclinical data on the therapeutic potential, pharmacology, and mechanism of action of nomlabofusp as a novel frataxin (FXN) protein replacement therapy designed to address the underlying cause of Friedreich's ataxia (FA). note: Data included in the briefing package reviewed by the U.S. Food and Drug Administration (FDA) in support of potentially using skin FXN concentrations as a reasonably likely surrogate endpoint (RLSE) for Larimar's registrational program seeking accelerated approval for nomlabofusp.

1 · Reply

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

Jun 23, 2025, 7:00 AM EDT - 22 days ago

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Jun 20, 2025, 4:05 PM EDT - 25 days ago

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Apr 30, 2025, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Mar 24, 2025, 7:00 AM EDT - 4 months ago

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:05 PM EST - 4 months ago

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Jan 23, 2025, 4:05 PM EST - 6 months ago

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Jan 3, 2025, 5:49 PM EST - 6 months ago

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Dec 17, 2024, 1:39 PM EST - 7 months ago

What's Going On With Larimar Therapeutics Stock On Tuesday?

Dec 16, 2024, 12:17 PM EST - 7 months ago

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

Dec 16, 2024, 7:00 AM EST - 7 months ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Oct 30, 2024, 7:00 AM EDT - 9 months ago

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 16, 2024, 2:59 PM EDT - 9 months ago

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oct 6, 2024, 9:28 PM EDT - 10 months ago

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Sep 19, 2024, 7:00 AM EDT - 10 months ago

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

May 31, 2024, 4:11 PM EDT - 1 year ago

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 30, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

May 20, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

May 9, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Mar 6, 2024, 4:05 PM EST - 1 year ago

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 16, 2024, 4:20 PM EST - 1 year ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 6:15 AM EST - 1 year ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Feb 13, 2024, 4:18 PM EST - 1 year ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Feb 12, 2024, 7:00 AM EST - 1 year ago

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Nov 14, 2023, 7:00 AM EST - 1 year ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 1, 2023, 4:05 PM EDT - 1 year ago

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Oct 3, 2023, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 2, 2023, 6:02 AM EDT - 2 years ago

Larimar: Friedreich's Ataxia Drug With Significant Potential

Jul 25, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Jun 21, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Set to Join Russell 3000® Index

May 15, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

Mar 28, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

Mar 14, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

Feb 7, 2023, 4:05 PM EST - 2 years ago

Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer

Nov 21, 2022, 4:05 PM EST - 2 years ago

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

Nov 10, 2022, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

Nov 7, 2022, 4:05 PM EST - 2 years ago

Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

Oct 20, 2022, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601

Oct 19, 2022, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

Sep 26, 2022, 9:59 AM EDT - 3 years ago

MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An Edge

AAPL AMGN CAT CELH CLFD CVX DOW

Sep 16, 2022, 1:00 PM EDT - 3 years ago

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

Sep 14, 2022, 7:04 AM EDT - 3 years ago

Larimar Therapeutics Announces $70 Million Underwritten Offering

Sep 14, 2022, 7:01 AM EDT - 3 years ago

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich's Ataxia Patients

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results

Jul 28, 2022, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders

Buss Jul. 13 at 7:37 PM

0 · Reply

Buss Jul. 13 at 7:28 PM

0 · Reply

Biobullshitsniffer Jul. 12 at 3:41 PM

$LRMR Huge options calls expiring in November.

0 · Reply

Buss Jul. 10 at 10:42 PM

0 · Reply

Primitivetablemaker Jul. 9 at 2:14 PM

$SYTA $LRMR $RNAZ

0 · Reply

Buss Jul. 9 at 1:01 AM

$LRMR "The Heat Is On" :) https://www.youtube.com/watch?v=uZD8HKVKneI&list=RDuZD8HKVKneI&start_radio=1

0 · Reply

Buss Jul. 9 at 1:00 AM

0 · Reply

Musket1776 Jul. 8 at 5:46 PM

1 · Reply

Dani_G_German Jul. 8 at 2:32 PM

$LRMR

0 · Reply

G101SPM Jul. 8 at 11:08 AM

1 · Reply

roquefort Jul. 7 at 11:57 PM

$LRMR Open label extension study 50mg dose readout of skin Frataxin levels in Sept 2025. Through its START pilot program, the FDA has signaled openness to using skin Frataxin concentration as a surrogate endpoint for nomlabofusp’s Biologics License Application (BLA). Hoping for a runup this month and next into September data release.

1 · Reply

Primitivetablemaker Jul. 7 at 1:42 PM

$LRMR holding

0 · Reply

Chartist0_0 Jul. 3 at 10:50 AM

$LRMR bull flag breakout in better volume. White line is the 200 day and a natural resistance point first time up.

0 · Reply

Buss Jul. 2 at 8:52 PM

$LRMR Classic bull flag breakout. First target 4'ish which poses major resistance as it battles headwinds,if light volume, every step of the way. 200 day MA @ 4.21 ultimate challenge but could be a great spot to take profits. MACD set to turn positive as well.

0 · Reply

Buss Jul. 2 at 4:02 PM

$LRMR 2-min Ichimoku Senkou Span A should provide very nice support for next advance thru today's high of 3.19

0 · Reply

Chartist0_0 Jul. 2 at 2:31 PM

$LRMR bull flagging. 4.20$ coming up?

1 · Reply

roquefort Jul. 1 at 7:40 PM

$LRMR Nomlabofusp: Orphan Drug Designation, Fast Track Designation, Rare Pediatric Disease Designation, START Pilot Program Selection. US TAM 1-2 billion. WW TAM 3-5 billion. LRMR market cap is currently 0.186 billion. Phase 2 dose exploration study already complete with positive top-line data, no serious adverse events. September catalyst coming.

0 · Reply

Dani_G_German Jun. 27 at 3:20 PM

$LRMR 6/17/25

2 · Reply

Chartist0_0 Jun. 27 at 2:36 PM

$LRMR languishes into mid August on lack of news.

1 · Reply

Dani_G_German Jun. 27 at 1:29 AM

$LRMR closed above 3 is bullish af! 3.45 next stop then 3.82

1 · Reply

Buss Jun. 26 at 8:51 PM

$LRMR Hourly set-up poised perfectly for next price advance as per Ichimoku Cloud analysis. Further confirmation established once TK-Cross occurs (i.e., bullish crossover of tenken over kijun, which equates to the ST MA in yellow crossing over the LT MA in violet). All other parameters are presently met.

0 · Reply

Buss Jun. 26 at 7:13 PM

$LRMR Dang...tried to double-up @ 2.87...never filled. :( Regardless, let's hope that was the last shot at that level.

0 · Reply

Market Cap	216.42M
Revenue (ttm)	0.00
Net Income (ttm)	-80.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	853,445
Avg Vol	1,291,978
Day's Range	N/A - N/A
Shares Out	64.03M
Stochastic %K	74%
Beta	0.86
Analysts	Strong Sell
Price Target	$20.90